Scarica l'app Stockscreener
0.4218
2.11%
0.0087
Dopo l'orario di chiusura:
.42
-0.0018
-0.43%
Precedente Chiudi:
$0.4131
Aprire:
$0.4109
Volume 24 ore:
424.41K
Relative Volume:
0.54
Capitalizzazione di mercato:
$124.57M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-0.5339
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+4.25%
1M Prestazione:
-2.72%
6M Prestazione:
-59.05%
1 anno Prestazione:
-84.20%
Intervallo 1D:
$0.4001
$0.4254
Intervallo di 1 settimana:
$0.39
$0.4463
Portata 52W:
$0.39
$2.85
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta LYEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.4218 | 119.49M | 54,000 | -210.26M | -159.01M | -0.79 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post
Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline - TipRanks
Lyell Immunopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lyell Immunopharma Reports Clinical Progress and Financial Results for LYL314 CAR T-Cell Therapy Targeting Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewswire
Breakthrough Lymphoma Treatment: Lyell's Dual-Target Therapy Achieves 94% Response Rate in Clinical Trial - Stock Titan
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
LYEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Lyell Immunopharma Announces Oral Presentation of New - GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - Stock Titan
Renaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Inc [LYEL] Records 200-Day SMA of $0.9472 - knoxdaily.com
Geode Capital Management LLC Raises Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Financial Metrics Check: Lyell Immunopharma Inc (LYEL)’s Ratios for Trailing Twelve Months - DWinneX
A better buy-in window may exist right now for Lyell Immunopharma Inc (LYEL) - Sete News
Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 35,640 shares worth 19958.0. - knoxdaily.com
Can you now get a good deal on Lyell Immunopharma Inc’s shares? - uspostnews.com
Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Receives “Neutral” Rating from HC Wainwright - The AM Reporter
FDA grants RMAT status to Lyell’s lymphoma therapy By Investing.com - Investing.com South Africa
Lyell Immunopharma gets FDA RMAT status for lymphoma treatment - Seeking Alpha
FDA grants RMAT status to Lyell’s lymphoma therapy - Investing.com
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewswire
Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients - Stock Titan
Prudential Financial Inc. Cuts Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Lyell Immunopharma stock hits 52-week low at $0.4 - Investing.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition - Fierce Pharma
Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Lyell Immunopharma director Otis Brawley purchases shares for $19,958 By Investing.com - Investing.com India
Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com
Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com
Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks
Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com
Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat
Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 200,000 shares worth 0.12 million. - knoxdaily.com
Wednesday 3/26 Insider Buying Report: LYEL, LSAK - Nasdaq
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com
Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa
Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.33%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):